AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.
Saved in:
| Title: | AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response. |
|---|---|
| Authors: | Schuiveling M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands. Electronic address: m.schuiveling@umcutrecht.nl., van Duin IAJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands., Ter Maat LS; Image Sciences Institute, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands., van der Weerd JC; Department of Pathology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713 GZ, the Netherlands., Verheijden RJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands., van den Berkmortel F; Department of Medical Oncology, Zuyderland Medical Center Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen 6162 BG, the Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands., Breimer GE; Department of Pathology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands., Burgers FH; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands., Boers-Sonderen M; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen 6525 GA, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam 1081 Hz, the Netherlands., de Groot JWB; Isala Oncology Center, Isala, Dokter van Heesweg 2, Zwolle 8025 AB, the Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands; Division of Molecular Oncology and Immunology, Oncode Institute, Amsterdam 1066 CX, the Netherlands; Melanoma Clinic, Center Hospitalier Universitaire Vaudois, Lausanne 1005, Switzerland., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713 GZ, the Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede 7512 KZ, the Netherlands., Simkens L; Department of Internal Medicine, Maxima Medical Center, De Run 4600, Eindhoven 5504 DB, the Netherlands., Westgeest HM; Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda 4818 CK, the Netherlands., Schrader AMR; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, the Netherlands., Pluim JPW; Medical Image Analysis, Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Eindhoven 5600 MB, the Netherlands., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands., Blokx WAM; Department of Pathology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands., Veta M; Medical Image Analysis, Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Eindhoven 5600 MB, the Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CG, the Netherlands. |
| Source: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 Jun 25; Vol. 242, pp. 116831. Date of Electronic Publication: 2026 May 25. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
